+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07195227

Phase 2 Study of Camizestrant and Ribociclib Treatment in Adults With Hormone Receptor Positive Breast Cancer

Led by MedSIR · Updated on 2026-05-29

150

Participants Needed

16

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of combining ribociclib, a drug that inhibits certain proteins involved in cell growth, with camizestrant, a medication that blocks estrogen receptors, in treating advanced hormone receptor-positive breast cancer. This phase II study focuses on patients who have previously received hormone therapy for at least five years, including at least two years of aromatase inhibitor treatment. The main goal is to determine how long patients remain free from disease progression when treated with this combination. Participants will receive ribociclib orally at 600 mg daily for the first 21 days of each 28-day cycle, along with camizestrant taken orally at 75 mg every day throughout each 28-day cycle. The study includes an experimental treatment group receiving both drugs and a comparator group using historical data from previous clinical trials. This approach allows researchers to assess the combinations safety and effectiveness over time. During the study, participants will undergo regular assessments to monitor disease progression, response to treatment, and quality of life for up to 28 months. The research team will evaluate various outcomes such as progression-free survival, overall response rate, and patient-reported quality of life. Safety will also be closely monitored by tracking any adverse events. Participants are expected to attend scheduled visits for evaluations and provide tissue samples when available.

CONDITIONS

Brief Title

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Research Team

M

MEDSIR

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here